Regeneron Pharmaceuticals Inc. (REGN) Rating Reiterated by RBC Capital Markets
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)‘s stock had its “outperform” rating restated by stock analysts at RBC Capital Markets in a research note issued on Tuesday. They presently have a $648.00 target price on the biopharmaceutical company’s stock. RBC Capital Markets’ price objective suggests a potential upside of 65.05% from the company’s previous close.
A number of other research analysts also recently weighed in on the company. Goldman Sachs Group Inc. reiterated a “buy” rating and set a $521.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 27th. Jefferies Group reiterated a “hold” rating on shares of Regeneron Pharmaceuticals in a report on Wednesday, August 17th. Vetr downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $419.76 price target on the stock. in a report on Monday, July 11th. Chardan Capital downgraded Regeneron Pharmaceuticals to a “sell” rating and set a $325.00 price target on the stock. in a report on Wednesday, June 8th. Finally, Zacks Investment Research upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $472.00 price target on the stock in a report on Tuesday, August 9th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and eleven have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $480.09.
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) opened at 392.60 on Tuesday. Regeneron Pharmaceuticals has a 52 week low of $329.09 and a 52 week high of $592.59. The firm has a 50-day moving average price of $403.07 and a 200-day moving average price of $391.73. The firm has a market capitalization of $41.08 billion, a price-to-earnings ratio of 61.25 and a beta of 1.31.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported $2.82 earnings per share for the quarter, beating analysts’ consensus estimates of $2.65 by $0.17. Regeneron Pharmaceuticals had a return on equity of 23.77% and a net margin of 15.65%. The business had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.24 billion. During the same quarter in the previous year, the company posted $2.89 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 21.4% compared to the same quarter last year. On average, equities analysts expect that Regeneron Pharmaceuticals will post $11.00 earnings per share for the current fiscal year.
In related news, Director Joseph L. Goldstein sold 2,125 shares of the business’s stock in a transaction dated Friday, July 29th. The stock was sold at an average price of $425.00, for a total transaction of $903,125.00. Following the completion of the transaction, the director now owns 15,125 shares of the company’s stock, valued at approximately $6,428,125. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 10.40% of the company’s stock.
Several institutional investors have recently bought and sold shares of REGN. Franklin Resources Inc. boosted its position in Regeneron Pharmaceuticals by 4.8% in the first quarter. Franklin Resources Inc. now owns 667,283 shares of the biopharmaceutical company’s stock valued at $240,516,000 after buying an additional 30,562 shares in the last quarter. BlackRock Institutional Trust Company N.A. boosted its position in Regeneron Pharmaceuticals by 0.7% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 1,961,289 shares of the biopharmaceutical company’s stock valued at $706,927,000 after buying an additional 13,215 shares during the period. Nikko Asset Management Americas Inc. purchased a new position in Regeneron Pharmaceuticals during the first quarter valued at approximately $216,000. NN Investment Partners Holdings N.V. purchased a new position in Regeneron Pharmaceuticals during the first quarter valued at approximately $1,477,000. Finally, Shufro Rose & Co. LLC purchased a new position in Regeneron Pharmaceuticals during the first quarter valued at approximately $1,203,000. 68.16% of the stock is owned by institutional investors and hedge funds.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.